USPTO serial 76113583
DESADENOSINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 7, 2003
- Examiner
- MICHOS, JOHN E
- Law office
- SCANNING ON DEMAND
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with DESADENOSINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
EPIGENESIS Pharmaceuticals, Inc.
Cranbury, NJ
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Dr. Viviana Amzel
DR VIVIANA AMZEL EPIGENESIS PHARMACEUTICALS, INC7 CLARKE DRCRANBURY, NJ 08512UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Describing and providing medical diagnostic and pharmaceutical preparations with nucleotide sequences that have a low content of, or fully lack, adenosine, for testing, preventing, and therapeutically treating human and non-human animal respiratory ailments that may be associated with hyper-sensitivity or hyper-responsiveness to adenosine, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in many cases are adenosine receptor associated symptoms; pharmaceutical preparations for the treatment of airway and pulmonary diseases and conditions, such as asthma, pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, Acute Respiratory Distress Syndrome (ARDS), renal damage and failure, ischemia, resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating SupraVentricular Tachycardia (SVT), adenosine stress tests, infantile Respiratory Distress Syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vascoconstriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, e.g., colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, etc., as well as all other metastatic cancers, e.g., cancers which metastasized to the lung(s), breast, liver and prostate | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by EPIGENESIS Pharmaceuticals, Inc.
- Other trademarks owned by EPIGENESIS Pharmaceuticals, Inc.
- Other trademarks owned by EPIGENESIS Pharmaceuticals, Inc.
- Other trademarks in Class 005
- Similar marks named DESADENOSINE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 15, 2009 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Jan 17, 2008 | CFIT | CASE FILE IN TICRS | — |
| Jan 7, 2003 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 15, 2002 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2002 | NPUB | NOTICE OF PUBLICATION | — |
| Mar 5, 2002 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 27, 2001 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 22, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2001 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 16, 2001 | DOCK | ASSIGNED TO EXAMINER | — |